Neither HIV-positive status (aOR 0.91; 95% CI 0.57-1.47) nor carotid intima-media thickness (aOR 1.17; 95% CI 0.77-1.79) were significantly associated with neurocognitive impairment.
Cross-Sectional (n=442)
HIV infection and neurocognitive impairment (n=442)
HIV-positive status vs HIV-negative status
Neurocognitive impairment (NCI) — aOR 0.91 (0.57-1.47), p=.71
Effect estimate: aOR 0.91 (95% CI 0.57-1.47)
Absolute Event Rate: 59.4% vs 61.7%
p-value: p=.71
Neurocognitive impairment (NCI) contributes to poor quality of life among HIV-positive individuals. Cardiovascular risk factors, including the predictor of subclinical atherosclerosis, carotid intima-media thickness (cIMT), are reported to be associated with NCI. Data on NCI and its association with cIMT among HIV positive are limited, especially in Asian populations. We aimed to determine the prevalence of NCI and its association with cIMT among HIV-positive and HIV-negative aging Thai individuals. Cognitive performance was evaluated by the Thai version of Montreal Cognitive Assessment (MoCA) with a cutoff of <25/30 for diagnosis of NCI. Depression was evaluated by PHQ-9 Patient Depression Questionnaire, with scores ≥5 indicating depression. cIMT measurement was performed by experienced neurologists, and abnormal cIMT was defined as cIMT ≥0.9 mm or presence of carotid plaques. Among 340 well suppressed and aging HIV-positive and 102 HIV-negative matched participants, the median age (interquartile range) was 55 (52–59) years and 61.5% were males. For HIV positive group, the median duration on antiretroviral therapy was 18.3 years with median CD4 of 615.5 cells/mm 3 , and 97.4% had current plasma HIV RNA <50 copies/mL. The most common antiretroviral agents used were tenofovir disoproxil fumarate (76.8%), lamivudine (70.3%), efavirenz (26.7%), and emtricitabine (23.8%). HIV-positive and HIV-negative participants performed comparably between each domain and had comparable prevalence of NCI (59.4% vs. 61.7%, p = .69). However, the HIV-positive group had a high prevalence of depression (24.71% vs. 13.73%, p = .019). HIV-positive status adjusted odd ratio (aOR) 0.91; 95% confidence interval (CI) 0.57–1.47, p = .71 and cIMT (aOR 1.17; 95% CI 0.77–1.79, p = .47) were not significantly associated with NCI. Given the high prevalence of NCI and depression among aging HIV-positive individuals, routine screening for NCI and depression should be integrated into the HIV care services.
Building similarity graph...
Analyzing shared references across papers
Loading...
Akarin Hiransuthikul
Thai Red Cross Society
Aurauma Chutinet
Cross-Cutting Cardiology
Salila Sakulrak
AIDS Research and Human Retroviruses
Chulalongkorn University
King Chulalongkorn Memorial Hospital
HIV Netherlands Australia Thailand Research Collaboration
Building similarity graph...
Analyzing shared references across papers
Loading...
Hiransuthikul et al. (Sat,) conducted a cross-sectional in HIV infection and neurocognitive impairment (n=442). HIV-positive status vs. HIV-negative status was evaluated on Neurocognitive impairment (NCI) (aOR 0.91, 95% CI 0.57-1.47, p=.71). Neither HIV-positive status (aOR 0.91; 95% CI 0.57-1.47) nor carotid intima-media thickness (aOR 1.17; 95% CI 0.77-1.79) were significantly associated with neurocognitive impairment.
synapsesocial.com/papers/6a09abe6e5a55b25c0513738 — DOI: https://doi.org/10.1089/aid.2019.0139